Vanderbilt-Ingram Cancer Center

Adding radioligand therapy to first-line treatment of grade 2 or grade 3 gastroenteropancreatic neuroendocrine tumors conferred a significant reduction in risk for disease progression or death, results of a randomized study showed.

Treatment with fruquintinib resulted in a significant and clinically meaningful survival benefit when compared with placebo among patients with refractory metastatic colorectal cancer, according to data published in The Lancet.

CHICAGO — Pembrolizumab plus axitinib continued to confer a survival benefit vs. sunitinib at 5-year follow-up as first-line therapy for patients with advanced clear cell renal cell carcinoma, according to study results.

Often regarded in oncology as a complementary diagnostic or early detection tool, liquid biopsy has moved into routine clinical use to help guide treatment decisions in the era of targeted, molecular-based therapies.

First responders to the World Trade Center had higher rates of clonal hematopoiesis-associated mutations than firefighters not exposed to the dust, gases and potential carcinogens at the site, according to a study in Nature Medicine.

SALT LAKE CITY — Axatilimab appeared effective for heavily pretreated patients with active chronic graft-versus-host disease, according to phase 1/phase 2 study results.

Ben Ho Park, MD, PhD, has been appointed director of Vanderbilt-Ingram Cancer Center.

Jennifer Pietenpol, PhD, director of Vanderbilt-Ingram Cancer Center, will step down from that position this summer to focus on a new combined leadership role.

Radiation prior to combination immunotherapy did not influence clinical outcomes among patients with metastatic renal cell carcinoma and bone metastases, according to study results presented at International Kidney Cancer Symposium.

The Association of Community Cancer Centers announced recipients of its 11th annual Innovator Awards.